KZIA's Multi‑Asset Pipeline and Strong Balance Sheet Defy Market Sell‑off
$KZIA looks interesting after Friday's sell-off. The move felt more like sympathy pressure from the broader oncology tape following the $CELC ASCO reaction than anything company-specific. A few things stand out: > Paxalisib continues advancing in Phase 1b TNBC, with early signals suggesting potential immune modulation and tumor burden reduction. Expansion cohorts and potential additional indications remain on the horizon. > The PD-L1 degrader program could become an underappreciated catalyst. Early preclinical/translational data are expected within the next couple of months. The market appears focused on recent PI3K disappointment after $CELC. But $KZIA isn't a one-asset story. Paxalisib is a brain-penetrant PI3K/AKT/mTOR inhibitor and the company is also building a differentiated PD-L1 degrader platform. Balance sheet also looks stronger than many micro-cap biotech peers: ~$46M cash + access to a $50M non-equity credit facility, with burn running around ~$1M/month. Multiple shots on goal, several near-term catalysts, and a valuation that looks disconnected from the upcoming news flow.
IMMX's NXC-201 Shows 95
We have been fans of $IMMX for some time, and the recent selloff is creating what looks like an interesting opportunity in what may be one of the more disruptive cell therapy platforms in development. • NXC-201 has reported a...
IMMX Russell 2000 Addition Tight
$IMMX added to the Russell 2000 is exactly the type of setup that can tighten float dynamics fast. Passive buying. More institutional screens. More forced attention. Meanwhile NXC-201 data keeps improving and the market still doesn’t fully appreciate the AL amyloidosis opportunity.
IMMX Secures $150M at $8.94 to Fund NXC-201
$IMMX prices $150M underwritten offering at $8.94/share, with proceeds expected to fund continued NXC-201 development and extend operational runway into mid-2028. Morgan Stanley and BofA Securities are leading the deal. Read more: https://t.co/QxQsiNNXbz
Kazia’s Paxalisib Shows >50% CTC Drop, Early Responses
Kazia Therapeutics ($KZIA) is a catalyst-driven setup centered on upcoming ASCO data from their Paxalisib drug development platform. The update is following earlier disclosures from their ongoing Phase 1b ABC-Pax study evaluating paxalisib in metastatic triple-negative breast cancer (TNBC) showing...
AI Drug Discovery: Hype Overwhelms Real Clinical Success
AI Drug Discovery – Revolution or Expensive Illusion? | Ep. 978 https://t.co/YLQ8QNlnWv [ 00:34 ] Billions into AI drug discovery [ 01:04 ] AI doesn’t cure diseases [ 01:38 ] Expensive illusion vs reality [ 02:23 ] Original pitch inefficiency problem [ 03:48 ] Only 10...
Biotech's Confidence Game Masks Uncertainty and Risk
The Confidence Game in Biotech | Ep. 972 https://t.co/RyMgyMVr54 [ 01:12 ] when that trial works [ 01:30 ] manufactured certainty trap [ 02:02 ] linear mental model failure [ 02:33 ] relay race of risk [ 03:31 ] durability risk reality [ 05:29 ] compressing uncertainty...
IMMX Completes NEXICART‑2 Enrollment, Paving Path
$IMMX hits a big milestone: NEXICART-2 enrollment complete BLA-enabling Strong prior efficacy (~75% CR) No approved therapies in R/R AL https://t.co/0iUBMaSetC
Oral GLP‑1 Battle Heats up Amid FDA Uncertainty
Oral GLP-1 wars, FDA drift, HIV franchise defense, and a few biotech landmines | Ep. 970 https://t.co/sx4kBXzgSL [ 02:30 ] oral GLP-1 battlefield heats up [ 03:08 ] convenience factor drives adoption [ 04:51 ] tolerability issues hit persistence [ 05:45 ] Novo writes $2.1...
Morgan Stanley Sets $20 Target, 120% Upside for IMMX
$IMMX - Morgan Stanley initiates coverage with a $20 PT and an outperform rating, implying ~120% upside. https://t.co/Pd4uIH5BkI
Biotech Winter: Funding Freeze, IPO Surge, Path to Thaw
Biotech Science at Less Than Zero | Ep. 955 https://t.co/4DXKsaKXdO [00:49] Biotech capital winter deep dive [01:17] Scientific leaps vs frozen markets [02:31] The 2020–2021 biotech bubble [03:42] Crossover funds fuel IPO surge [04:56] Interest rates freeze biotech funding [07:58] Negative enterprise value phenomenon [10:37] Why Big Pharma...
Patent Battles and GLP‑1 Turf Wars Prompt FDA Crackdown
Patent Fights, GLP-1 Turf Wars, and the FDA Tightens the Screws | Ep. 952 https://t.co/v0fulR3NfB https://t.co/9gGdkAVvlv
Ribosome-Targeted Drugs Redefine Psychiatry and Beyond
Ribosomes as Drug Targets. The Quiet Rewrite of Psychiatry and Beyond. | Ep. 950 https://t.co/gKlWpzO1Ci https://t.co/ImGOmUVrSO
Psychedelic Stocks Overhyped as Nominee Warns Caution
Psychedelic tape still trades on vibes > policy. Surgeon General nominee Casey Means says she “would not recommend” psilocybin to the American people today. Yes, she nods to “exciting work” in PTSD and veterans. But that is a far cry from...
AI Should Boost Human Response Rates, Not Invent New Drugs
$LTRN is a live experiment in our thesis: AI doesn’t need to invent new drugs. It needs to improve probability of success in humans. If RADR consistently enriches responders, that’s durable value. If not, platform premium disappears. Listen to the podcast here: https://t.co/ZAg5btpcIK